Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | BCL2 | P10415 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27658629 | 0.85 | KDM4E (0.47) | GAAHTTCA1CA2GABRA1 | |
| Benzene SCHEMBL9247233 | 0.83 | BCL2 (0.46) | GAAHTTCA1CA2GABRA1 | |
| SCHEMBL9945914 | 0.82 | SMN1; SMN2 (0.38) | GAAHTTLMNA | |
| SCHEMBL910132 | 0.81 | KDM4E (0.47) | HTTCA2MCL1ALDH1A1 | |
| SCHEMBL5337349 | 0.81 | GABRA1 (0.57) | GAAHTTCA1CA2GABRA1 | |
| SCHEMBL13640204 | 0.81 | CA1 (0.43) | GAAHTTCA1CA2GABRA1 | |
| SCHEMBL13640243 | 0.80 | PKM (0.42) | GAAHTTCA1CA2GABRA1 | |
| SCHEMBL6837803 | 0.79 | GABRA1 (0.64) | GAAHTTCA1CA2GABRA1 | |
| SCHEMBL544651 | 0.79 | CA1 (0.67) | GAAHTTCA1CA2GABRA1 | |
| SCHEMBL471443 | 0.75 | KDM4E (0.46) | GAACA1CA2MCL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283335-A1 | Analogs of Propofol, Preparation Thereof and Use as Anesthetics | SIGNATURE THERAPEUTICS, INC. | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283335-A1 | Analogs of Propofol, Preparation Thereof and Use as Anesthetics | GABRP, CYP4F11, CYP2F1 | GAA 4268/4885HTT 2402/4885CA1 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.